KRAS and metastatic malignant neoplasm in the lymph nodes: Schmid et al. reported that the KRAS and EGFR gene status in primary tumors and lymph node metastases were discordant in 25 (26%) and 6 (6.25%) patients among 96 patients, respectively [26].